Using advanced MRI techniques to evaluate diabetic kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of multimodal magnetic resonance imaging (MRI) in diagnosing and monitoring diabetic kidney disease (DKD). It aims to establish a non-invasive method for assessing DKD progression by combining imaging techniques with biochemical indicators. Diabetic patients at various stages of DKD will undergo regular MRI examinations to explore the relationship between imaging findings and kidney function changes. The goal is to improve the accuracy of DKD diagnosis and treatment monitoring without the need for invasive procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinically diagnosed diabetic kidney disease (DKD)
* Age 18-80 years

Exclusion Criteria:

* Malignant tumor, active infection, or life expectancy \<1 year
* Pregnancy or lactation
* MRE contraindications (metal implants, claustrophobia, severe arrhythmia) or poor image quality
* eGFR \<15 mL/min/1.73m² or receiving renal replacement therapy
* Other primary kidney diseases or systemic diseases affecting renal function

Where it's running

• Shengjing Hospital
  Shenyang, Liaoning, China Recruiting

Study contacts

• Principal investigator: Yu Shi, M.D. — Shengjing Hospital
• Study coordinator: Yu Shi, M.D.
• Email: 18940259980@163.com
• Phone: 18940259980

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MTX-439 safety test in healthy adults and adults with diabetic kidney disease

  This phase 1 study tests MTX-439 in healthy adults and adults with diabetic kidney disease to see if it is safe and how the body handles it.

  Recruiting Phase 1 Mediar Therapeutics · Melbourne, Victoria · NCT07473323

• Pharmacist prescribing to improve kidney care for people with type 2 diabetes

  This project will test whether pharmacist prescribing guided by step-by-step algorithms helps adults with type 2 diabetes and early diabetic kidney disease who lack a regular doctor start recommended kidney‑protecting medications.

  Recruiting Nova Scotia Health Authority · Halifax, Nova Scotia · NCT07169422

• Formoterol for diabetic kidney disease

  This trial will test whether adding formoterol fumarate to usual care helps adults with type 2 diabetes who have moderate diabetic kidney disease.

  Recruiting Phase 2 Medical University of South Carolina · Charleston, South Carolina · NCT07022418

• Effects of low oxygen levels on kidney function in healthy individuals and diabetes patients

  This study is testing how low oxygen levels affect kidney function in healthy people and those with diabetes to see if there are different risks for kidney health.

  Recruiting Poitiers University Hospital · Poitiers · NCT06846034

• AP303 safety, tolerability, and dosing in people with diabetic kidney disease

  This study will try a 2-week oral dose of AP303 or placebo in adults with type 2 diabetic kidney disease to see if it is safe and how the body processes it.

  Recruiting Phase 1 Alebund Pharmaceuticals · Beijing, Beijing Municipality · NCT06666283

• Evaluating R3R01 for reducing protein in urine for diabetic kidney disease

  This study is testing if a new drug called R3R01 can help adults with type 2 diabetes and kidney disease lower the protein in their urine and improve their kidney function.

  Recruiting Phase 2 River 3 Renal Corp. · Copenhagen, Copenhagen · NCT06600412

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.